3045 related articles for article (PubMed ID: 23566846)
1. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
2. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
4. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
6. Engineering better immunotherapies via RNA interference.
Sioud M
Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
8. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
Draghiciu O; Lubbers J; Nijman HW; Daemen T
Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
11. Biological drug and drug delivery-mediated immunotherapy.
Xiao Q; Li X; Li Y; Wu Z; Xu C; Chen Z; He W
Acta Pharm Sin B; 2021 Apr; 11(4):941-960. PubMed ID: 33996408
[TBL] [Abstract][Full Text] [Related]
12. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
13. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
14. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines, electroporation and their applications in cancer treatment.
Lee SH; Danishmalik SN; Sin JI
Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
[TBL] [Abstract][Full Text] [Related]
16. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
19. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]